Innate Pharma S.A. (NASDAQ:IPHA) Short Interest Update

Innate Pharma S.A. (NASDAQ:IPHA) was the target of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 65,200 shares, an increase of 10.9% from the October 15th total of 58,800 shares. Based on an average daily trading volume, of 8,400 shares, the short-interest ratio is presently 7.8 days.

Innate Pharma Price Performance

IPHA traded up $0.09 during midday trading on Monday, reaching $1.53. 41,648 shares of the company were exchanged, compared to its average volume of 9,219. The stock’s 50-day simple moving average is $2.02 and its 200 day simple moving average is $2.23. Innate Pharma has a one year low of $1.29 and a one year high of $3.15.

Analyst Ratings Changes

A number of equities analysts have issued reports on IPHA shares. HC Wainwright reaffirmed a “buy” rating and issued a $11.50 price objective on shares of Innate Pharma in a research note on Tuesday, November 12th. Evercore ISI raised Innate Pharma to a “strong-buy” rating in a research note on Monday, September 16th.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.